Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience-Reference-Cited by-同舟云学术

Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience

Published:2021-09-28 Issue:4 Volume:2 Page:774-784
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Sonnevi Kristina¹²,Ljungqvist Maria¹³,Jóelsson Jóel Kristinn¹³^ORCID,Harrysson Sara¹³^ORCID,Wästerlid Tove¹³^ORCID,Bernell Per¹³,Wahlin Björn Engelbrekt¹²^ORCID

Affiliation:

1. Haematology Medical Unit Karolinska University Hospital Stockholm Sweden

2. Division of Haematology, Department of Medicine, Huddinge Karolinska Institutet Stockholm Sweden

3. Division of Haematology, Department of Medicine Karolinska Institutet Stockholm Sweden

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.296

Reference34 articles.

1. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

2. Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

3. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group

4. Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

5. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Оптимизация терапии у пациентов с впервые диагностированной диффузной В-крупноклеточной лимфомой: эффективность и безопасность программы R-SD-EPOCH ± HDMTX в рамках одноцентрового нерандомизированного проспективного клинического исследования (предварительные результаты);Clinical Oncohematology;2024-04-01